Comparative Pharmacology of Cephalosporins and Sulfonylureas: Mechanisms, Clinical Applications, and Safety

Keywords

Abstract

References

1. [1]Gastrointestinal and dermatological effects The interaction assessment should extend beyond prescription medicines to non-prescription products, dietary supplements, alcohol consumption, irregular eating patterns, and acute illness. Patients should be advised not to independently change doses in response to a suspected interaction without appropriate professional guidance. These classes differ in their effects on insulin sensitivity, urinary glucose excretion, incretin signalling, body weight, cardiovascular outcomes, and renal outcomes. Sulfonylureas remain valuable in some circumstances because of their efficacy, oral administration, clinical familiarity, and comparatively low acquisition cost. Cephalosporin monitoring may involve clinical response, microbiological findings, renal function, hypersensitivity symptoms, gastrointestinal complications, and selected laboratory parameters according to the agent and treatment context. Sulfonylurea monitoring centres on blood glucose, symptoms of hypoglycaemia, glycated haemoglobin, meal regularity, renal and hepatic function, and weight. The appropriate monitoring strategy depends on the patient’s risk profile and the wider diabetes regimen. The rational selection of a cephalosporin depends on the organism, infection site, severity, local resistance patterns, allergy history, renal function, and availability of alternatives. The rational selection of a sulfonylurea depends on glycaemic goals, β-cell function, hypoglycaemia risk, nutritional stability, renal and hepatic function, comorbidities, affordability, and patient preference. Author contributions: Devanssh Mehta: conceptualisation, literature review, synthesis, and manuscript preparation. Acknowledgements: None declared. Patel P, Preuss CV. Cephalosporins. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated 2024 Feb 17. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551517/ Mora-Ochomogo M, Lohans CT. β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates. RSC Med Chem. 2021;12(10):1623–1639. Doi:10.1039/D1MD00200G. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2022;75(2):187–212. Doi:10.1093/cid/ciab1013. American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S158–S178. Doi:10.2337/dc24-S009. American Journal of PharmTech Research. Author guidelines and submission instructions [Internet]. Available from: https://ajptr.com/author-guidelines and https://ajptr.com/submit-paper. Accessed 21 October 2026.

Authors (1)